» Articles » PMID: 37658085

Acquired MiR-142 Deficit in Leukemic Stem Cells Suffices to Drive Chronic Myeloid Leukemia into Blast Crisis

Abstract

The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of miR-142 in CD34CD38 blasts from BC CML patients than in those from CP CML patients, suggesting that miR-142 deficit is implicated in BC evolution. Thus, we create miR-142 knockout CML (i.e., miR-142BCR-ABL) mice, which develop BC and die sooner than miR-142 wt CML (i.e., miR-142BCR-ABL) mice, which instead remain in CP CML. Leukemic stem cells (LSCs) from miR-142BCR-ABL mice recapitulate the BC phenotype in congenic recipients, supporting LSC transformation by miR-142 deficit. State-transition and mutual information analyses of "bulk" and single cell RNA-seq data, metabolomic profiling and functional metabolic assays identify enhanced fatty acid β-oxidation, oxidative phosphorylation and mitochondrial fusion in LSCs as key steps in miR-142-driven BC evolution. A synthetic CpG-miR-142 mimic oligodeoxynucleotide rescues the BC phenotype in miR-142BCR-ABL mice and patient-derived xenografts.

Citing Articles

miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.

Chen F, Zhao D, Xu Y, Zhang Y, Chen M, Pathak K Nat Commun. 2025; 16(1):1253.

PMID: 39893171 PMC: 11787332. DOI: 10.1038/s41467-025-56383-y.


PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.

Zhou M, Huang Y, Xu P, Li S, Duan C, Lin X Adv Sci (Weinh). 2024; 12(5):e2308586.

PMID: 39668478 PMC: 11791931. DOI: 10.1002/advs.202308586.


Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.

Zeng C, Nie D, Wang X, Zhong S, Zeng X, Liu X Mol Cancer. 2024; 23(1):240.

PMID: 39465372 PMC: 11514791. DOI: 10.1186/s12943-024-02162-0.


CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML.

Absar M, Alanazi N, Siyal A, Shammas M, Mahmood A, Basit S J Popul Ther Clin Pharmacol. 2024; 29(2):311-320.

PMID: 38465242 PMC: 10923263. DOI: 10.53555/jptcp.v29i02.4161.


Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development.

Goldberg L, Haas E, Urak R, Vyas V, Pathak K, Garcia-Mansfield K Cancer Res. 2024; 84(7):1048-1064.

PMID: 38315779 PMC: 10984768. DOI: 10.1158/0008-5472.CAN-23-2299.


References
1.
OConnor R, Guo L, Ghassemi S, Snyder N, Worth A, Weng L . The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018; 8(1):6289. PMC: 5908836. DOI: 10.1038/s41598-018-24676-6. View

2.
Brillo V, Chieregato L, Leanza L, Muccioli S, Costa R . Mitochondrial Dynamics, ROS, and Cell Signaling: A Blended Overview. Life (Basel). 2021; 11(4). PMC: 8070048. DOI: 10.3390/life11040332. View

3.
Jamieson C, Ailles L, Dylla S, Muijtjens M, Jones C, Zehnder J . Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-67. DOI: 10.1056/NEJMoa040258. View

4.
Broadhurst D, Goodacre R, Reinke S, Kuligowski J, Wilson I, Lewis M . Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics. 2018; 14(6):72. PMC: 5960010. DOI: 10.1007/s11306-018-1367-3. View

5.
Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View